Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis

Journal of Cystic Fibrosis

Volumn 14, Issue 1, 2015, Pages 42-45

  Budding, K ^a   van de Graaf, E A ^a   Hoefnagel, T ^a   Kwakkel van Erp, J M ^a   van Kessel, D A ^b   Dragun, D ^c   Hack, C E ^a   Otten, H G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AT1R; Autoantibodies; Cystic fibrosis; ETAR; Lung transplantation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; BASILIXIMAB; BIOLOGICAL MARKER; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; MYCOPHENOLIC ACID; TACROLIMUS; VALGANCICLOVIR;

ADOLESCENT; ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BRONCHIOLITIS OBLITERANS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CYSTIC FIBROSIS; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE COURSE; ELISA KIT; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERSTITIAL LUNG DISEASE; LANGERHANS CELL HISTIOCYTOSIS; LUNG FIBROSIS; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; MALE; SYSTEMIC SCLEROSIS; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATIENT SELECTION; PILOT STUDY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; CYSTIC FIBROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PILOT PROJECTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84918826609     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.07.007     Document Type: Article

References (15)

1. Kerem E., Reisman J., Corey M., Canny G.J., Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med Apr 30 1992, 326(18):1187-1191.
2. Tiriveedhi V., Gautam B., Sarma N.J., Askar M., Budev M., Aloush A., et al. Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations. J Heart Lung Transplant Aug 2013, 32(8):807-814.
3. Lachenal F., Nkana K., Nove-Josserand R., Fabien N., Durieu I. Prevalence and clinical significance of autoantibodies in adults with cystic fibrosis. Eur Respir J Nov 2009, 34(5):1079-1085.
4. Green C.M., Low T.B., O'Neill S.J., McElvaney N.G. Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med Jan 1 2010, 181(1):31-35.
5. Carlsson M., Eriksson L., Pressler T., Kornfalt R., Mared L., Meyer P., et al. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. J Cyst Fibros May 2007, 6(3):228-233.
6. Siahanidou T., Nicolaidou P., Doudounakis S., Georgouli E., Papadimitriou A., Karpathios T. Plasma immunoreactive endothelin levels in children with cystic fibrosis. Acta Paediatr Aug 2000, 89(8):915-920.
7. Charpin J.M., Stern M., Lebrun G., Aubin P., Grenet D., Israel-Biet D. Increased endothelin-1 associated with bacterial infection in lung transplant recipients. Transplantation Jun 27 2001, 71(12):1840-1847.
8. Jeppsson A., Tazelaar H.D., Miller V.M., McGregor C.G. Distribution of endothelin-1 in transplanted human lungs. Transplantation Sep 27 1998, 66(6):806-809.
9. Riemekasten G., Philippe A., Nather M., Slowinski T., Muller D.N., Heidecke H., et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis Mar 2011, 70(3):530-536.
10. Cooper J.D., Billingham M., Egan T., Hertz M.I., Higenbottam T., Lynch J., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant Sep-Oct 1993, 12(5):713-716.
11. Chalmers G.W., Macleod K.J., Sriram S., Thomson L.J., McSharry C., Stack B.H., et al. Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease. Eur Respir J Jun 1999, 13(6):1288-1292.
12. Roland M., Bhowmik A., Sapsford R.J., Seemungal T.A., Jeffries D.J., Warner T.D., et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax Jan 2001, 56(1):30-35.
13. Salama M., Jaksch P., Andrukhova O., Taghavi S., Klepetko W., Aharinejad S. Endothelin-1 is a useful biomarker for early detection of bronchiolitis obliterans in lung transplant recipients. J Thorac Cardiovasc Surg Dec 2010, 140(6):1422-1427.
14. Hiemann N.E., Meyer R., Wellnhofer E., Schoenemann C., Heidecke H., Lachmann N., et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation Nov 15 2012, 94(9):919-924.
15. Dragun D., Catar R., Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant Aug 2013, 18(4):430-435.